Schering-Plough/Aveo Will Develop Novel Cancer Biologic Based On Biomarkers
This article was originally published in The Pink Sheet Daily
Executive Summary
Schering gains access to preclinical antibody, as well as biomarker profiling technology in deal worth up to $477.5 million
You may also be interested in...
Japan's Kirin, Kyowa Merge To Strengthen Biotechnology Focus
Kirin Holdings and Kyowa Hakko will seek to bring together each company's strength in biotech to create a global research and development-centered Japanese drug company. The two Tokyo-based companies announced a merger agreement Oct. 22, reflecting the ongoing consolidation of the Japanese drug industry
Japan’s Kirin, Kyowa Merge To Strengthen Biotechnology Focus
Kirin will acquire a 50.1 percent stake in Kyowa Hakko in a deal valued at close to ¥300 billion ($2.64 billion).
Japan’s Kirin, Kyowa Merge To Strengthen Biotechnology Focus
Kirin will acquire a 50.1 percent stake in Kyowa Hakko in a deal valued at close to ¥300 billion ($2.64 billion).